Hexagon Nutrition Q1 FY27 Revenue Up 43.2% to ₹104.3 Cr, PAT Grows 25.1%
Hexagon Nutrition reported Q1 FY27 consolidated revenue of ₹104.3 crore, up 43.2% YoY. PAT grew 25.1% to ₹8.1 crore. EBITDA was ₹11.8 crore, up 17.3%. The company expects a 20-25% revenue growth for FY27 and aims for its branded business to reach 35% of total revenue in two years.
The announcement details significant financial growth and strategic outlook for the company, which is material for investors and the market.
The company reported strong year-on-year growth in revenue, EBITDA, and profit after tax, indicating a positive financial performance.
Hexagon Nutrition Limited announced its Q1 FY27 results, with consolidated revenue from operations reaching ₹104.3 crore, a significant increase of 43.2% from ₹72.9 crore in Q1 FY26. The company reported a 17.3% year-on-year growth in EBITDA to ₹11.8 crore and a 25.1% increase in profit after tax (PAT) to ₹8.1 crore.
The company highlighted the strong performance driven by continued demand for its nutrition solutions across domestic and international markets. Dr. Nikhil Kelkar, Joint Managing Director, noted that this quarter marks their first results announcement post-listing on BSE and NSE in June 2026. He emphasized the growing opportunity in the nutrition sector due to increasing awareness around preventive healthcare and specialized nutrition.
The diversified business model, spanning micronutrient premixes, clinical nutrition, therapeutic nutrition, food fortification, and consumer nutrition, enables Hexagon Nutrition to cater to various market segments. The company continues to invest in R&D for innovative formulations and maintains a focus on quality and operational efficiency across its manufacturing facilities.
Vikram Kelkar, Managing Director, elaborated on the performance across business segments. The micronutrient premix business remains a key growth engine, supported by increasing adoption of fortified food products. The clinical and wellness nutrition business, featuring brands like PentaSure, PediaGold, and Obesigo, is expanding its reach into Tier 2 and Tier 3 cities and digital channels.
Financially, the company reported a gross profit of ₹45.8 crore, a 34.1% increase year-on-year. EBITDA margin stood at 11.3%, with management attributing the dip from 13.8% in Q1 FY26 to business mix and strategic investments. Profit before tax grew by 25.1% to ₹10.6 crore.
Looking ahead, Hexagon Nutrition aims for a 20-25% revenue growth trajectory for FY27, with a focus on sustainable growth, international presence expansion, innovation, operational efficiencies, and disciplined capital allocation. The company expects its branded business to contribute significantly, potentially reaching 35% of total revenue in the next couple of years.
What to do with a filing like this
Hexagon Nutrition Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Hexagon Nutrition Limited. Read the original for the full detail.